Trastuzumab: beside a new treatment under test

261 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 3. Open to participants first (55), then studies with results posted, then the rest; newest registration first within each.

Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast CancerNot yet recruitingNCT07857226Phase 2 Report a problem
A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer PatientsNot yet recruitingNCT07824869Phase 2 Report a problem
Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBCRecruitingNCT07797218Phase 3 Report a problem
Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast CancerNot yet recruitingNCT07795424Phase 2 Report a problem
SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast CancerNot yet recruitingNCT07787338Phase 2 Report a problem
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerNot yet recruitingNCT07766772Phase 2 Report a problem
Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding StudyRecruitingNCT07739511Phase 1/2 Report a problem
Culmerciclib in HR+/HER2+ Advanced Breast CancerRecruitingNCT07732491Phase 2 Report a problem
Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast CancerNot yet recruitingNCT07716046Phase 2 Report a problem
Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMDRecruitingNCT07694986Phase 2 Report a problem
Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast CancerRecruitingNCT07647263Phase 2 Report a problem
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast CancerRecruitingNCT07616427Phase 2 Report a problem
Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast CancerRecruitingNCT07615751Phase 3 Report a problem
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerRecruitingNCT07610720Phase 2 Report a problem
Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast CancerRecruitingNCT07600164Phase 4 Report a problem
Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast CancerRecruitingNCT07581795Phase 2 Report a problem
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveRecruitingNCT07413939Phase 2/3 Report a problem
ctDNA in HER2+ EBC Neoadjuvant TreatmentRecruitingNCT07335081Phase 2 Report a problem
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07315750Phase 3 Report a problem
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II StudyNot yet recruitingNCT07307287Phase 2 Report a problem
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast CancerNot yet recruitingNCT07246317Phase 2 Report a problem
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsRecruitingNCT07216105Phase 1 Report a problem
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II StudyNot yet recruitingNCT07179939Phase 2 Report a problem
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid TumorRecruitingNCT07140393Phase 1/2 Report a problem
HB1801 Combined Treatment of HER2-positive Breast CancerNot yet recruitingNCT07116824Phase 2 Report a problem
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast CancerNot yet recruitingNCT07093931Phase 4 Report a problem
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerRecruitingNCT07007559Phase 2 Report a problem
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical StudyRecruitingNCT06770296Phase 1 Report a problem
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)RecruitingNCT06686394Phase 1/2 Report a problem
Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsRecruitingNCT06625775Phase 1 Report a problem
A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid TumorsRecruitingNCT06555068Phase 1/2 Report a problem
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Phase 3 Report a problem
Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)Not yet recruitingNCT06510465Phase 2 Report a problem
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingNCT06324357Phase 1/2 Report a problem
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical StudyRecruitingNCT06254690Phase 2 Report a problem
A Phase 1/1b Study of IAM1363 in HER2 CancersRecruitingNCT06253871Phase 1 Report a problem
Safety and Efficacy of NK510 to Treat Gastric CancerEnrolling by invitationNCT06098898Early Phase 1 Report a problem
Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid TumorsNot yet recruitingNCT06027983Phase 1/2 Report a problem
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast CancerNot yet recruitingNCT05983094Phase 2 Report a problem
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant ChemotherapyRecruitingNCT05978648Phase 2 Report a problem
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BCRecruitingNCT05918328Phase 2 Report a problem
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast CancerNot yet recruitingNCT05841381Phase 3 Report a problem
A Study of DB-1310 in Advanced/Metastatic Solid TumorsRecruitingNCT05785741Phase 1/2 Report a problem
Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast CancerRecruitingNCT05720026Phase 3 Report a problem
Thero2-01S22 in HER2-positive Breast CancerNot yet recruitingNCT05698186Phase 3 Report a problem
Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast CancerNot yet recruitingNCT05430347Phase 2 Report a problem
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & PertuzumabRecruitingNCT05325632Phase 2 Report a problem
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerRecruitingNCT05306041Phase 2 Report a problem
Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast CancerRecruitingNCT05292742Phase 2 Report a problem
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast CancerRecruitingNCT05256745Phase 1/2 Report a problem
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal CancerRecruitingNCT05187182Phase 1 Report a problem
Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast CancerNot yet recruitingNCT04900311Phase 2 Report a problem
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast CancerRecruitingNCT04329065Phase 2 Report a problem
Adjuvant Study of Pyrotinib in HER-2 Positive Breast CancerRecruitingNCT04254263Phase 3 Report a problem
Study of eFT226 in Subjects With Selected Advanced Solid Tumor MalignanciesRecruitingNCT04092673Phase 1/2 Report a problem
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive CancersTerminatedNCT05091528Phase 1/2Results posted Report a problem
Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast CancerCompletedNCT04957212Phase 3Results posted Report a problem
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast CancerCompletedNCT03767335Phase 1Results posted Report a problem
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain MetastasesTerminatedNCT03765983Phase 2Results posted Report a problem
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast CancerActive, not recruitingNCT03414658Phase 2Results posted Report a problem
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast CancerCompletedNCT03364348Phase 1Results posted Report a problem
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.CompletedNCT03321981Phase 2Results posted Report a problem
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast CancerCompletedNCT03179904Phase 2Results posted Report a problem
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast CancerCompletedNCT03112590Phase 1/2Results posted Report a problem
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast CancerTerminatedNCT03101748Phase 1/2Results posted Report a problem
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal CancerCompletedNCT03043313Phase 2Results posted Report a problem
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast CancerCompletedNCT02675231Phase 2Results posted Report a problem
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.CompletedNCT02657343Phase 1/2Results posted Report a problem
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast CancerCompletedNCT02614794Phase 2Results posted Report a problem
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)TerminatedNCT02393248Phase 1/2Results posted Report a problem
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the BrainCompletedNCT02308020Phase 2Results posted Report a problem
Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer PatientsCompletedNCT02297698Phase 2Results posted Report a problem
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast CancerTerminatedNCT02154529Phase 1/2Results posted Report a problem
STAR Cape+BKM120 MBC With Brain MetCompletedNCT02000882Phase 2Results posted Report a problem
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsTerminatedNCT01953926Phase 2Results posted Report a problem
Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody TherapyCompletedNCT01922921Phase 1/2Results posted Report a problem
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast CancerCompletedNCT01816594Phase 2Results posted Report a problem
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and StomachTerminatedNCT01774851Phase 2Results posted Report a problem
A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast CancerCompletedNCT01674062Phase 2Results posted Report a problem
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast CancerCompletedNCT01670877Phase 2Results posted Report a problem
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.CompletedNCT01649271Phase 1Results posted Report a problem
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination RegimenCompletedNCT01587040Phase 1/2Results posted Report a problem
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast CancerCompletedNCT01572038Phase 3Results posted Report a problem
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVaxCompletedNCT01570036Phase 2Results posted Report a problem
A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast CancerCompletedNCT01565083Phase 2Results posted Report a problem
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast CancerCompletedNCT01491737Phase 2Results posted Report a problem
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric CancerCompletedNCT01461057Phase 2Results posted Report a problem
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerCompletedNCT01358877Phase 3Results posted Report a problem
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid MalignanciesCompletedNCT01351350Phase 1Results posted Report a problem
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast CancerCompletedNCT01276041Phase 2Results posted Report a problem
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor MalignanciesCompletedNCT01235897Phase 1Results posted Report a problem
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast CancerTerminatedNCT01220128Phase 2Results posted Report a problem
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast CancerTerminatedNCT01132664Phase 1/2Results posted Report a problem
MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast CancerCompletedNCT01097460Phase 1Results posted Report a problem
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)CompletedNCT01026142Phase 3Results posted Report a problem
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast CancerCompletedNCT00976989Phase 2Results posted Report a problem
A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)TerminatedNCT00963547Phase 1Results posted Report a problem
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)TerminatedNCT00954512Phase 1/2Results posted Report a problem
Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.CompletedNCT00950742Phase 1Results posted Report a problem
Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast CancerCompletedNCT00847171Phase 2Results posted Report a problem

← Trastuzumab